LIVIVO - Search results -

Search results

Result 1 - 10 of total 44

Search options

Article ; Online: Encouraging but slow progress toward incorporating obesity care into diabetes care.

Almandoz, Jaime P / Lingvay, Ildiko

2023 Volume 31, Issue 12, Page(s) 2893–2894

MeSH term(s)	Humans ; Diabetes Mellitus, Type 2/prevention & control ; Obesity/therapy
Language	English
Publishing date	2023-11-05
Publishing country	United States
Document type	Journal Article
ZDB-ID	2230457-5
ISSN	1930-739X ; 1071-7323 ; 1930-7381
ISSN (online)	1930-739X
ISSN	1071-7323 ; 1930-7381
DOI	10.1002/oby.23925
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 4061: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (2.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MG 87: Show issues

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾
- See ZB MED holdings
- Order with fees

Article: Editorial: Approaches to the management of weight regain after bariatric surgery.

Shah, Meera / Almandoz, Jaime P / Shukla, Alpana P

Frontiers in endocrinology

2023 Volume 14, Page(s) 1267014

MeSH term(s)	Humans ; Weight Gain ; Bariatric Surgery ; Body Weight Maintenance
Language	English
Publishing date	2023-08-14
Publishing country	Switzerland
Document type	Editorial
ZDB-ID	2592084-4
ISSN	1664-2392
ISSN	1664-2392
DOI	10.3389/fendo.2023.1267014
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Response to "Sampling and data missingness in Almandoz et al."

Almandoz, Jaime P / Xie, Luyu / Schellinger, Jeffrey N / Mathew, M Sunil / Messiah, Sarah E

Obesity (Silver Spring, Md.)

2023 Volume 31, Issue 4, Page(s) 890–891

Language	English
Publishing date	2023-02-28
Publishing country	United States
Document type	Letter
ZDB-ID	2230457-5
ISSN	1930-739X ; 1071-7323 ; 1930-7381
ISSN (online)	1930-739X
ISSN	1071-7323 ; 1930-7381
DOI	10.1002/oby.23696
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 4061: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (2.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MG 87: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Obesity among Latinx people in the United States: A review.

Alemán, José Orlando / Almandoz, Jaime P / Frias, Juan Pablo / Galindo, Rodolfo J

Obesity (Silver Spring, Md.)

2023 Volume 31, Issue 2, Page(s) 329–337

Abstract: Obesity is a serious, chronic disease that is associated with a range of adiposity-based comorbidities, including cardiovascular disease, type 2 diabetes, and nonalcoholic fatty liver disease. In the United States, obesity is a public health crisis, ... ...

Abstract	Obesity is a serious, chronic disease that is associated with a range of adiposity-based comorbidities, including cardiovascular disease, type 2 diabetes, and nonalcoholic fatty liver disease. In the United States, obesity is a public health crisis, affecting more than 40% of the population. Obesity disproportionately affects Latinx people, who have a higher prevalence of obesity and related comorbidities (such as cardiovascular disease, type 2 diabetes, and nonalcoholic fatty liver disease) compared with the general population. Many factors, including genetic predisposition, environmental factors, traditional calorie-dense Latinx diets, family dynamics, and differences in socioeconomic status, contribute to the increased prevalence and complexity of treating obesity in the Latinx population. Additionally, significant heterogeneity within the Latinx population and disparities in health care access and utilization between Latinx people and the general population add to the challenge of obesity management. Culturally tailored interventions have been successful for managing obesity and related comorbidities in Latinx people. Antiobesity medications and bariatric surgery are also important options for obesity treatment in Latinx people. As highlighted in this review, when managing obesity in the Latinx population, it is critical to consider the impact of genetic, dietary, cultural, and socioeconomic factors, in order to implement an individualized treatment strategy.
MeSH term(s)	Humans ; Cardiovascular Diseases/ethnology ; Diabetes Mellitus, Type 2/ethnology ; Hispanic or Latino ; Non-alcoholic Fatty Liver Disease/ethnology ; Obesity/ethnology ; Obesity/therapy ; United States/epidemiology ; Health Status Disparities
Language	English
Publishing date	2023-01-24
Publishing country	United States
Document type	Journal Article ; Review ; Research Support, Non-U.S. Gov't
ZDB-ID	2230457-5
ISSN	1930-739X ; 1071-7323 ; 1930-7381
ISSN (online)	1930-739X
ISSN	1071-7323 ; 1930-7381
DOI	10.1002/oby.23638
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 4061: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (2.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MG 87: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: What is clinically relevant weight loss for your patients and how can it be achieved? A narrative review.

Horn, Deborah B / Almandoz, Jaime P / Look, Michelle

Postgraduate medicine

2022 Volume 134, Issue 4, Page(s) 359–375

Abstract: Obesity is a chronic disease with increasing prevalence. It affects quality of life and renders those affected at increased risk of mortality. For people living with obesity, weight loss is one of the most important strategies to improve health outcomes ... ...

Abstract	Obesity is a chronic disease with increasing prevalence. It affects quality of life and renders those affected at increased risk of mortality. For people living with obesity, weight loss is one of the most important strategies to improve health outcomes and prevent or reverse obesity-related complications. In line with newly released clinical practice guidelines, weight loss targets for people living with obesity should be defined individually based on their clinical profile, and progress measured in the context of improvements in health outcomes, rather than weight loss alone. We outline current treatment options for clinically meaningful weight loss and briefly discuss pharmacological agents and devices under development. Numerous studies have shown that weight loss of ≥5% results in significant improvements in cardiometabolic risk factors associated with obesity; this degree of weight loss is also required for the approval of novel anti-obesity medications by the US Food and Drug Administration. However, some obesity-related comorbidities and complications, such as non-alcoholic steatohepatitis, obstructive sleep apnea, gastroesophageal reflux disease and remission of type 2 diabetes, require a greater magnitude of weight loss to achieve clinically meaningful improvements. In this review, we assessed the available literature describing the effect of categorical weight losses of ≥5%, ≥10%, and ≥15% on obesity-related comorbidities and complications, and challenge the concept of clinically meaningful weight loss to go beyond percentage change in total body weight. We discuss weight-loss interventions including lifestyle interventions and therapeutic options including devices, and pharmacological and surgical approaches as assessed from the available literature.
MeSH term(s)	Anti-Obesity Agents/therapeutic use ; Diabetes Mellitus, Type 2/drug therapy ; Humans ; Obesity/drug therapy ; Obesity/therapy ; Quality of Life ; Weight Loss
Chemical Substances	Anti-Obesity Agents
Language	English
Publishing date	2022-04-26
Publishing country	England
Document type	Journal Article ; Review
ZDB-ID	410138-8
ISSN	1941-9260 ; 0032-5481
ISSN (online)	1941-9260
ISSN	0032-5481
DOI	10.1080/00325481.2022.2051366
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Ua VI Zs.407: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Sleeve Gastrectomy for Weight Loss.

Puzziferri, Nancy / Almandoz, Jaime P

JAMA

2018 Volume 319, Issue 3, Page(s) 316

MeSH term(s)	Gastrectomy/adverse effects ; Gastrectomy/methods ; Humans ; Nausea/etiology ; Obesity, Morbid/surgery ; Thrombosis/etiology ; Weight Loss
Language	English
Publishing date	2018--16
Publishing country	United States
Document type	Patient Education Handout
ZDB-ID	2958-0
ISSN	1538-3598 ; 0254-9077 ; 0002-9955 ; 0098-7484
ISSN (online)	1538-3598
ISSN	0254-9077 ; 0002-9955 ; 0098-7484
DOI	10.1001/jama.2017.18519
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Ua VI Zs.88: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Pharmacotherapies for Post-Bariatric Weight Regain: Real-World Comparative Outcomes.

Gazda, Chellse L / Clark, John D / Lingvay, Ildiko / Almandoz, Jaime P

Obesity (Silver Spring, Md.)

2021 Volume 29, Issue 5, Page(s) 829–836

Abstract: ... P < 0.001] for ILM, non-GLP-1-RA-based WLP, and GLP-1-RA-based WLP groups, respectively), 6 months ... 0.8% vs. 2.9% vs. 6.7% [P < 0.001]), and 9 months (-1.6% vs. 5.6% vs. 6.9% [P = 0.007]). There was ...

Abstract	Objective: This study aimed to compare outcomes of treatment strategies for weight regain after bariatric surgery. Methods: This is a retrospective analysis of 207 individuals treated for post-bariatric weight regain at an academic center from January 1, 2014, through November 25, 2019. Percentage body weight loss was compared after 3, 6, 9, and 12 months of treatment among an intensive lifestyle modification (ILM) group, a non-glucagon-like-1 receptor agonist (GLP-1-RA)-based weight-loss pharmacotherapy (WLP) group, and a GLP-1-RA-based WLP group (the latter two groups in conjunction with ILM). Results: The percentage body weight loss was significantly different between groups after 3 months (1.4% vs. 2.2% vs. 4.5% [P < 0.001] for ILM, non-GLP-1-RA-based WLP, and GLP-1-RA-based WLP groups, respectively), 6 months (0.8% vs. 2.9% vs. 6.7% [P < 0.001]), and 9 months (-1.6% vs. 5.6% vs. 6.9% [P = 0.007]). There was a significant difference in the percentage of individuals achieving ≥5% weight loss after 3, 6, and 9 months, with most occurring in the GLP-1-RA-based WLP group. In a multiple regression analysis including bariatric surgery type, treatment group was the only significant predictor of percentage weight change. Conclusions: GLP-1-RA-based WLP therapies were found to be more effective for treating post-bariatric weight regain than non-GLP-1-RA-based WLP or ILM, regardless of surgery type.
MeSH term(s)	Adult ; Bariatric Surgery/adverse effects ; Drug Therapy/methods ; Female ; Humans ; Male ; Middle Aged ; Retrospective Studies ; Treatment Outcome ; Weight Gain/physiology
Language	English
Publishing date	2021-04-04
Publishing country	United States
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	2230457-5
ISSN	1930-739X ; 1071-7323 ; 1930-7381
ISSN (online)	1930-739X
ISSN	1071-7323 ; 1930-7381
DOI	10.1002/oby.23146
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 4061: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (2.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MG 87: Show issues

Order via subito

Details ▾

Article: Switching Between Glucagon-Like Peptide-1 Receptor Agonists: Rationale and Practical Guidance.

Almandoz, Jaime P / Lingvay, Ildiko / Morales, Javier / Campos, Carlos

Clinical diabetes : a publication of the American Diabetes Association

2020 Volume 38, Issue 4, Page(s) 390–402

Language	English
Publishing date	2020-10-25
Publishing country	United States
Document type	Journal Article
ZDB-ID	1025953-3
ISSN	0891-8929
ISSN	0891-8929
DOI	10.2337/cd19-0100
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 2591: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Effectiveness of semaglutide versus liraglutide for treating post-metabolic and bariatric surgery weight recurrence.

Murvelashvili, Natia / Xie, Luyu / Schellinger, Jeffrey N / Mathew, M Sunil / Marroquin, Elisa Morales / Lingvay, Ildiko / Messiah, Sarah E / Almandoz, Jaime P

Obesity (Silver Spring, Md.)

2023 Volume 31, Issue 5, Page(s) 1280–1289

Abstract: Objective: The aim of this study was to compare the effectiveness of semaglutide versus liraglutide for treating post-metabolic and bariatric surgery (MBS) weight recurrence.: Methods: A retrospective analysis of 207 adults with post-MBS weight ... ...

Abstract	Objective: The aim of this study was to compare the effectiveness of semaglutide versus liraglutide for treating post-metabolic and bariatric surgery (MBS) weight recurrence. Methods: A retrospective analysis of 207 adults with post-MBS weight recurrence treated with semaglutide 1.0 mg weekly (n = 115) or liraglutide 3.0 mg daily (n = 92) at an academic center from January 1, 2015, through April 1, 2021, was conducted. The primary end point was percentage body weight change at 12 months of treatment with regimens containing semaglutide or liraglutide. Results: The mean sample age was 55.2 years; mean BMI was 40.4 kg/m Conclusions: These results show that treatment regimens including semaglutide 1.0 mg weekly lead to superior weight loss compared with liraglutide 3.0 mg daily for treating post-MBS weight recurrence, regardless of procedure type or the magnitude of weight recurrence.
MeSH term(s)	Adult ; Female ; Humans ; Male ; Middle Aged ; Bariatric Surgery ; Liraglutide/pharmacology ; Liraglutide/therapeutic use ; Obesity, Morbid/drug therapy ; Obesity, Morbid/surgery ; Retrospective Studies ; Treatment Outcome ; Weight Loss ; Weight Gain/drug effects ; Postoperative Period ; Glucagon-Like Peptides/pharmacology ; Glucagon-Like Peptides/therapeutic use ; Hypoglycemic Agents/pharmacology ; Hypoglycemic Agents/therapeutic use
Chemical Substances	Liraglutide (839I73S42A) ; semaglutide (53AXN4NNHX) ; Glucagon-Like Peptides (62340-29-8) ; Hypoglycemic Agents
Language	English
Publishing date	2023-03-30
Publishing country	United States
Document type	Journal Article
ZDB-ID	2230457-5
ISSN	1930-739X ; 1071-7323 ; 1930-7381
ISSN (online)	1930-739X
ISSN	1071-7323 ; 1930-7381
DOI	10.1002/oby.23736
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 4061: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (2.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MG 87: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Association between asthma, obesity, and metabolic syndrome in adolescents and young adults.

Xie, Luyu / Chandrasekhar, Aparajita / Ernest, Deepali / Patel, Jenil / Afolabi, Folashade / Almandoz, Jaime P / Martinez Fernandez, Tanya / Gelfand, Andrew / Messiah, Sarah E

The Journal of asthma : official journal of the Association for the Care of Asthma

2023 Volume 61, Issue 4, Page(s) 368–376

Abstract: Background: The association of asthma and metabolic syndrome (MetS) among adolescents and young adults (AYAs) remains unclear, as well as the role of obesity in this relationship.: Methods: AYAs aged 12-25 years who participated in the 2011-2020 ... ...

Abstract	Background: The association of asthma and metabolic syndrome (MetS) among adolescents and young adults (AYAs) remains unclear, as well as the role of obesity in this relationship. Methods: AYAs aged 12-25 years who participated in the 2011-2020 National Health and Nutrition Examination Survey were included in this cross-sectional analysis. The moderating effect of obesity (age- and sex-adjusted body mass index ≥ 95th%ile for adolescents or ≥ 30 kg/m Results: A total of 7,709 AYAs (53.9% aged 12-18 years, 51.1% males, and 54.4% non-Hispanic White) were included in this analysis. 3.6% (95% CI 2.8-4.3%) had obesity and asthma, 7.6% (95% CI 6.8-8.4%) had asthma and no obesity, 21.4% (95% CI 19.6-23.2%) had obesity and no asthma, and 67.4% (95% CI 65.4-69.4%) had neither obesity nor asthma. The estimated prevalence of MetS was greater among those with both obesity and asthma versus those with only asthma (4.5% [95% CI 1.7-7.3%] vs. 0.2% [95% CI 0-0.5%], Conclusions: Our results show the association between MetS and asthma is stronger in AYAs with BMI-defined obesity. Efforts to prevent and treat obesity may reduce MetS occurrence in AYAs with asthma.
MeSH term(s)	Male ; Humans ; Adolescent ; Young Adult ; Female ; Metabolic Syndrome/epidemiology ; Nutrition Surveys ; Cross-Sectional Studies ; Asthma/epidemiology ; Asthma/complications ; Obesity/epidemiology ; Obesity/complications ; Body Mass Index ; Prevalence
Language	English
Publishing date	2023-11-11
Publishing country	England
Document type	Journal Article
ZDB-ID	603816-5
ISSN	1532-4303 ; 0277-0903
ISSN (online)	1532-4303
ISSN	0277-0903
DOI	10.1080/02770903.2023.2280763
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.B 18: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

To top

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito